Abstract INTRODUCTION Early identification of amyloid‐beta (Aβ) pathology is essential for timely intervention in Alzheimer's disease (AD), as Aβ accumulation precedes clinical symptoms by years. METHODS We predicted positron emission tomography (PET) ‐defined Aβ status in cognitively normal individuals using non‐invas...
Bo-Xin Sun, Ming Gu, A. Maher et al.· Alzheimer's & Dementia· 0 citations
Tau pathology in the presence of Aβ was a stronger predictor of cognition in ADNI than in U.S. POINTER, and this discrepancy was not explained by increased vascular risk or brain atrophy in U.S. POINTER.
Pei-Wei Liu, Theresa M. Harrison, H. Snyder et al.· NeuroImage: Clinical· 0 citations
Findings support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification and support the potential value of EOAD-signature atrophy as an MRI-based biomarker for individualized prognostication and clinical trial stratification.
T. Paranhos, Yuta Katsumi, M. Brickhouse et al.· Neurology· 0 citations
A double-cutoff analysis suggest that scans in the 11 to 26 Centiloid range should be interpreted with caution depending on the context of use, and positivity cutoffs converged around 18 Centiloids (data-driven) and 27 Centiloids (visual reads).
G. Blazhenets, D. Soleimani-Meigooni, Konstantinos Chiotis et al.· Journal of the American Medi...· 5 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.